206 results Staatssteun, bestaanszekerheid en globalisering Deze blog gaat over de rol van het staatssteunrecht bij vraagstukken zoals bestaanszekerheid en de mondiale concurrentieverhoudingen. Hierbij worden ontwikkelingen zoals de oproep van industriële sectoren voor een European Industrial Deal betrokken. More state aid for green industry: the Clean Industrial State Aid Framework European industry must become less dependent on fossil fuels. To that end, the European Commission now allows state aid to support the transition towards a circular economy. Meer staatssteun voor groene industrie: het Clean Industrial State Aid Framework De Europese industrie moet minder afhankelijk worden van fossiele brandstoffen. De Europese Commissie maakt daarom meer staatssteun mogelijk voor overgang naar een circulaire economie. Tom Barkhuysen, Ali al Khatib en Ramses Walon leggen uit hoe het zit. C'est le ton qui fait la musique – The end of employer copyrights? The CJEU decision in the National Orchestra of Belgium decision shakes up employer copyright in the Netherlands. With new consent and compensation requirements, are your employment contracts still airtight? Discover the implications of the decision here. The long and (un)winding road of ‘killer acquisition’ Illumina/Grail Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal. If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines. Tom Verdonk Associate Amsterdam Pagination Previous page Page 9 Page 10 Page 11 Current page 12
Staatssteun, bestaanszekerheid en globalisering Deze blog gaat over de rol van het staatssteunrecht bij vraagstukken zoals bestaanszekerheid en de mondiale concurrentieverhoudingen. Hierbij worden ontwikkelingen zoals de oproep van industriële sectoren voor een European Industrial Deal betrokken.
More state aid for green industry: the Clean Industrial State Aid Framework European industry must become less dependent on fossil fuels. To that end, the European Commission now allows state aid to support the transition towards a circular economy.
Meer staatssteun voor groene industrie: het Clean Industrial State Aid Framework De Europese industrie moet minder afhankelijk worden van fossiele brandstoffen. De Europese Commissie maakt daarom meer staatssteun mogelijk voor overgang naar een circulaire economie. Tom Barkhuysen, Ali al Khatib en Ramses Walon leggen uit hoe het zit.
C'est le ton qui fait la musique – The end of employer copyrights? The CJEU decision in the National Orchestra of Belgium decision shakes up employer copyright in the Netherlands. With new consent and compensation requirements, are your employment contracts still airtight? Discover the implications of the decision here.
The long and (un)winding road of ‘killer acquisition’ Illumina/Grail Crystal ball gazing into prospective innovation rat races when assessing vertical mergers may soon be all in a day’s work for the European Commission. Innovation was a recurring theme in the Commission’s handling of the Illumina/Grail deal.
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.